ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0759

Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Development in a Population at Risk for Rheumatoid Arthritis
Abstract Number: 0760

X-rays Bone Erosions Are Uncommon in Anti-CCP Positive Individuals At-risk of Rheumatoid Arthritis with Musculoskeletal Symptoms Without Clinical Synovitis, and Do Not Predict the Development of Inflammatory Arthritis
Abstract Number: 0761

Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Risk of Progression to Rheumatoid Arthritis
Abstract Number: 0762

Anti-Protein-Arginine Deiminase (PAD) 1 IgG Is a Promising Novel Autoantigen in Rheumatoid Arthritis (RA) and Increases Diagnostic Performance in Combination with Anti-PAD4 IgG Using a Composite Biomarker Score
Abstract Number: 0763

Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
Abstract Number: 0764

Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data
Abstract Number: 0765

High Disease Activity at Baseline and Seropositivity Are Associated with Treatment Response at One Year Post Synovial Biopsy in RA Patients
Abstract Number: 0766

ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort
Abstract Number: 0767

Anti-acetylated Protein Antibodies in Rheumatoid Arthritis (RA): Clues for the Starting Point of Autoantibody Responses in RA
Abstract Number: 0768

Dynamics of Follicular Helper T Cells Subsets in Rheumatoid Arthritis Patients Before and After Treatment
Abstract Number: 0769

Does the Autoantibody-Response Mature Between Presentation with Arthralgia and Development of Rheumatoid Arthritis? – a Longitudinal Serological Study
Abstract Number: 0770

Effect of Citrullination on the Processing and Presentation of Rheumatoid Arthritis Autoantigens
Abstract Number: 0771

Factors Associated to Clinical and Radiographic Disease Progression in Patients with Early RA and First-degree Relatives: A 1-year Follow-up
Abstract Number: 0772

Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
Abstract Number: 0773

The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].